The estimated Net Worth of Michael M Rowe is at least $543 Mille dollars as of 28 August 2024. Mr. Rowe owns over 27,071 units of Eyenovia Inc stock worth over $61,599 and over the last 6 years he sold EYEN stock worth over $0. In addition, he makes $481,833 as Vice President - Commercial at Eyenovia Inc.
Sign up
Mr. Rowe EYEN stock SEC Form 4 insiders trading
Michael has made over 11 trades of the Eyenovia Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 27,071 units of EYEN stock worth $14,077 on 28 August 2024.
The largest trade he's ever made was buying 50,000 units of Eyenovia Inc stock on 26 August 2024 worth over $28,500. On average, Michael trades about 5,763 units every 114 days since 2018. As of 28 August 2024 he still owns at least 109,998 units of Eyenovia Inc stock.
You can see the complete history of Mr. Rowe stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Rowe biography
Michael M. Rowe serves as Vice President - Commercial of the Company. From February 2016 to June 2018, Mr. Rowe was head of Global Strategic Marketing, Ophthalmology at Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), where he was responsible for the United States and international commercialization, planning and execution for Rhopressa®, for the lowering of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Previously, he spent 12 years at Allergan plc (NYSE: AGN) in various roles supporting corporate strategic initiatives as well as strategic planning for the company’s worldwide glaucoma franchise, including the development of bimatoprost SR and the global launch of Ganfort® UD. Mr. Rowe also has held senior marketing roles at Bayer Healthcare Pharmaceuticals Inc., Women First HealthCare, Inc. (a former public company) and Pfizer Inc (NYSE: PFE). Mr. Rowe holds an M.Sc. in Human Factors/Experimental Psychology from Rensselaer Polytechnic Institute and a B.A. in Psychology from the State University of New York at Stony Brook.
What is the salary of Michael Rowe?
As the Vice President - Commercial of Eyenovia Inc, the total compensation of Michael Rowe at Eyenovia Inc is $481,833. There are 4 executives at Eyenovia Inc getting paid more, with Tsontcho Ianchulev having the highest compensation of $1,247,140.
How old is Michael Rowe?
Michael Rowe is 58, he's been the Vice President - Commercial of Eyenovia Inc since 2019. There are 8 older and 4 younger executives at Eyenovia Inc. The oldest executive at Eyenovia Inc is Ernest Mario, 81, who is the Independent Director.
What's Michael Rowe's mailing address?
Michael's mailing address filed with the SEC is C/O EYENOVIA, INC., 295 MADISON AVENUE, SUITE 2400, NEW YORK, NY, 10017.
Insiders trading at Eyenovia Inc
Over the last 7 years, insiders at Eyenovia Inc have traded over $1,275,000 worth of Eyenovia Inc stock and bought 6,072,235 units worth $17,599,075 . The most active insiders traders include Ernest Mario, Stuart M. Grant e Fredric N Eshelman. On average, Eyenovia Inc executives and independent directors trade stock every 31 days with the average trade being worth of $49,678. The most recent stock trade was executed by Michael M Rowe on 28 August 2024, trading 27,071 units of EYEN stock currently worth $14,077.
What does Eyenovia Inc do?
eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.
What does Eyenovia Inc's logo look like?
Complete history of Mr. Rowe stock trades at Eyenovia Inc
Eyenovia Inc executives and stock owners
Eyenovia Inc executives and other stock owners filed with the SEC include:
-
Tsontcho Ianchulev,
Chief Executive Officer, Director, Chief Medical Officer -
Dr. Tsontcho Ianchulev M.P.H., M.D., MPH,
CEO, Pres, Chief Medical Officer & Director -
John Gandolfo,
Chief Financial Officer, Secretary -
John P. Gandolfo CPA,
CFO & Sec. -
Michael Rowe,
Vice President - Commercial -
Jennifer Clasby,
Vice President - Clinical Operations -
Michael M. Rowe,
Chief Operating Officer -
Fredric Eshelman,
Independent Chairman of the Board -
Tram Bui,
IR Contact Officer -
Anthony Sun,
Independent Director -
Charles Mather,
Independent Director -
Ernest Mario,
Independent Director -
Kenneth Lee,
Independent Director -
Curt Labelle,
Director -
Luke Clauson,
Vice President - Research &Development and Manufacturing -
Norbert Lowe,
VP of Sales & Marketing -
Alexander Lobo,
Investor Contact -
Andrew D. Jones,
Chief Financial Officer -
Julia A Haller,
-
Bren Kern,
Chief Operating Officer -
Pharmaceutical Co., Ltd. Senju,
10% owner -
Shuhei Yoshida,
Director -
Stuart M. Grant,
-
Stephen Keith Benjamin,
-
Rachel Jacobson,
Director -
Ellen R Strahlman,
Director -
Michael S Geltzeiler,
Director -
Ram Palanki,
Director